ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Coronary Artery Disease
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1685953
This article is part of the Research TopicAdvancements in Understanding and Managing Residual Risk of Coronary Artery DiseasesView all articles
Expression of nucleotide-binding oligomerization domain (NOD)-like receptor protein 1 (NLRP1) in patients with acute myocardial infarction (AMI) and its relationship with clinical prognosis
Provisionally accepted- 1The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
- 2Xuzhou Medical University, Xuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Acute myocardial infarction (AMI) is the foremost cause of cardiovascular-related mortality worldwide, with inflammation significantly influencing its progression and prognosis. Nucleotide-binding oligomerization domain (NOD)-like receptor protein 1(NLRP1), a key inflammasome regulator, facilitates the release of pro-inflammatory factors. However, its expression profile in AMI and its relationship with inflammation and prognosis are not well understood. Methods: A total of 245 AMI patients (undergoing emergency Percutaneous Coronary Intervention (PCI) within 12 hours), 60 patients with unstable angina (UA), and 60 healthy controls were included. Serum NLRP1 levels were detected by enzyme-linked immunosorbent assay (ELISA), and clinical indicators were measured. AMI patients were followed up for 6 months to record major adverse cardiovascular events (MACE). Correlation analysis, regression models, and Receiver Operating Characteristic (ROC) curves were used to evaluate its prognostic value. Results: Serum NLRP1 levels increased with the severity of the disease (healthy controls < UA < AMI, P < 0.05), and were significantly correlated with inflammatory markers (such as high-sensitivity C-reactive protein [hs-CRP], Systemic Inflammatory Response Index [SIRI]) and myocardial injury markers (such as high-sensitivity cardiac troponin T [hs-cTnT]) in AMI patients (P < 0.05). A 6-month follow-up showed that AMI patients with MACE had higher NLRP1 levels (P < 0.001), and NLRP1 was an independent risk factor for MACE (OR = 1.01, P = 0.013). Stratified analyses showed that NLRP1 added predictive value, particularly in patients with low hs-cTnT and low SIRI, improving Area Under the Curve (AUC) (P < 0.05). The ROC curve indicated that NLRP1 alone had an AUC of 0.718 for predicting MACE, which increased to 0.822 when combined with traditional markers (P < 0.05). Category-free Net Reclassification Improvement (NRI) analysis showed a significant improvement in risk reclassification (NRI = 0.315, P = 0.037). Discussion: Serum NLRP1 levels correlate with coronary heart disease severity, indicating inflammation and myocardial injury, and independently predict short-term MACE in AMI. When combined with traditional markers, NLRP1 enhances prognostic assessment efficiency and holds potential as a novel inflammatory marker.
Keywords: NLRP1, acute myocardial infarction, Inflammation, MACE, biomarker
Received: 20 Aug 2025; Accepted: 30 Sep 2025.
Copyright: © 2025 Qian, Liu, Chen, Wu, Wang, Yao and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Fangfang Li, lifang8820@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.